NTCC™ Karpas-620人外周血浆细胞骨髓瘤细胞株IgG kappa plasma cell myeloma cell line BioVector NTCC典型培养物保藏中心

NTCC™Karpas-620 cell line is a human cell line used in oncology research, derived from the peripheral blood of a 77-year-old female patient with IgG kappa plasma cell leukemia in 1987. Plasma cell leukemia is a rare and aggressive form of multiple myeloma.

Key Characteristics

• Origin: The cells were established at the University of Cambridge from a patient's peripheral blood. They are classified as a lymphoid cell line, specifically a plasma cell myeloma type.

• Morphology: The cells grow in suspension and have the ultrastructural appearance of plasma cells, which includes abundant rough endoplasmic reticulum.

• Genetic Markers:

  • They secrete kappa light chains and are positive for surface antigens HLA DR and CD37. They are negative for CD1, CD3, CD4, and CD8.

  • The cells have a hypotetraploid karyotype and complex chromosomal aberrations, including translocations involving chromosomes 1, 11, and 14.

  • They express high levels of Cyclin D1 (CCND1) and have chromosomal abnormalities involving the c-myc locus.

Research Applications

The Karpas-620 cell line is a valuable tool for studying plasma cell leukemia and multiple myeloma, particularly for understanding the genetic and biological basis of these diseases. Its main applications include:

• Oncology Research: It serves as a model to study the progression and genetic makeup of plasma cell malignancies.

• Drug Sensitivity Screening: The cell line is used to test the effectiveness of new therapies, including chemotherapy drugs and targeted agents. For example, it has shown sensitivity to BCL-2 inhibitors like Venetoclax.

• Genetic Studies: The complex chromosomal translocations and gene expression patterns in Karpas-620 make it an important model for investigating the molecular pathways that drive these cancers.

BioVector NTCC质粒载体菌种细胞蛋白抗体基因保藏中心

BioVector NTCC Inc.

TEL: 400-800-2947, 189-0126-8599

E-mail: biovector@163.com

http://www.biovector.net

Karpas-620 细胞系是一种用于肿瘤学研究的人类细胞系，于1987年从一名77岁患有 IgG kappa 浆细胞白血病的女性患者的外周血中分离得到。浆细胞白血病是一种罕见且侵袭性强的多发性骨髓瘤。

主要特点

• 来源: 该细胞系在剑桥大学从患者的外周血中建立。它被归类为淋巴样细胞系，具体来说是浆细胞骨髓瘤类型。

• 形态: 这些细胞在悬浮培养中生长，具有浆细胞的超微结构外观，包括丰富的粗面内质网。

• 遗传标记:

  • 它们分泌 kappa 轻链，并且表面抗原 HLA DR 和 CD37 呈阳性。而 CD1、CD3、CD4 和 CD8 呈阴性。

  • 细胞具有亚四倍体核型和复杂的染色体畸变，包括涉及1号、11号和14号染色体的易位。

  • 它们表达高水平的 Cyclin D1 (CCND1)，并且具有涉及 c-myc 基因座的染色体异常。

研究应用

Karpas-620 细胞系是研究浆细胞白血病和多发性骨髓瘤的宝贵工具，尤其有助于理解这些疾病的遗传和生物学基础。其主要应用包括：

• 肿瘤学研究: 它可作为模型来研究浆细胞恶性肿瘤的进展和遗传构成。

• 药物敏感性筛选: 该细胞系用于测试新疗法（包括化疗药物和靶向药物）的有效性。例如，它已显示出对 BCL-2 抑制剂（如 Venetoclax）的敏感性。

• 遗传学研究: Karpas-620 复杂的染色体易位和基因表达模式使其成为研究驱动这些癌症的分子通路的重要模型。

BioVector NTCC质粒载体菌种细胞蛋白抗体基因保藏中心

BioVector NTCC Inc.

TEL: 400-800-2947, 189-0126-8599

E-mail: biovector@163.com

http://www.biovector.net